Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025
Published: December 9, 2025 Arcellx, Inc. (NASDAQ: ACLX) has jumped back onto Wall Street’s radar after releasing highly positive Phase 2 data for its multiple myeloma cell therapy anitocabtagene autoleucel (“anito-cel”) at the American Society of Hematology (ASH) 2025 meeting. The new data have driven a sharp move in the stock, a flurry of analyst updates, and renewed debate about valuation ahead of a planned 2026 commercial launch. Where Arcellx Stock Stands Today As of the close on December 9, 2025, Arcellx shares traded at $72.08, down about 2.7% on the day after a strong pre-market surge earlier in the